JP2019510733A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019510733A5 JP2019510733A5 JP2018530560A JP2018530560A JP2019510733A5 JP 2019510733 A5 JP2019510733 A5 JP 2019510733A5 JP 2018530560 A JP2018530560 A JP 2018530560A JP 2018530560 A JP2018530560 A JP 2018530560A JP 2019510733 A5 JP2019510733 A5 JP 2019510733A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- seq
- variable region
- chain variable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021049294A JP2021100957A (ja) | 2015-12-15 | 2021-03-23 | キメラ及びヒト化抗ヒトｃｔｌａ４モノクローナル抗体ならびにその使用 |
| JP2022096901A JP7286845B2 (ja) | 2015-12-15 | 2022-06-15 | キメラ及びヒト化抗ヒトｃｔｌａ４モノクローナル抗体ならびにその使用 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562267735P | 2015-12-15 | 2015-12-15 | |
| US62/267,735 | 2015-12-15 | ||
| US201662309169P | 2016-03-16 | 2016-03-16 | |
| US62/309,169 | 2016-03-16 | ||
| US201662359036P | 2016-07-06 | 2016-07-06 | |
| US62/359,036 | 2016-07-06 | ||
| PCT/US2016/066698 WO2017106372A1 (en) | 2015-12-15 | 2016-12-14 | Chimeric and humanized anti-human ctla4 monoclonal antibodies and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021049294A Division JP2021100957A (ja) | 2015-12-15 | 2021-03-23 | キメラ及びヒト化抗ヒトｃｔｌａ４モノクローナル抗体ならびにその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019510733A JP2019510733A (ja) | 2019-04-18 |
| JP2019510733A5 true JP2019510733A5 (enExample) | 2020-01-30 |
| JP6858779B2 JP6858779B2 (ja) | 2021-04-14 |
Family
ID=59057509
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018530560A Active JP6858779B2 (ja) | 2015-12-15 | 2016-12-14 | キメラ及びヒト化抗ヒトｃｔｌａ４モノクローナル抗体ならびにその使用 |
| JP2021049294A Pending JP2021100957A (ja) | 2015-12-15 | 2021-03-23 | キメラ及びヒト化抗ヒトｃｔｌａ４モノクローナル抗体ならびにその使用 |
| JP2022096901A Active JP7286845B2 (ja) | 2015-12-15 | 2022-06-15 | キメラ及びヒト化抗ヒトｃｔｌａ４モノクローナル抗体ならびにその使用 |
| JP2023085801A Active JP7790837B2 (ja) | 2015-12-15 | 2023-05-24 | キメラ及びヒト化抗ヒトｃｔｌａ４モノクローナル抗体ならびにその使用 |
| JP2025130097A Pending JP2025160458A (ja) | 2015-12-15 | 2025-08-04 | キメラ及びヒト化抗ヒトｃｔｌａ４モノクローナル抗体ならびにその使用 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021049294A Pending JP2021100957A (ja) | 2015-12-15 | 2021-03-23 | キメラ及びヒト化抗ヒトｃｔｌａ４モノクローナル抗体ならびにその使用 |
| JP2022096901A Active JP7286845B2 (ja) | 2015-12-15 | 2022-06-15 | キメラ及びヒト化抗ヒトｃｔｌａ４モノクローナル抗体ならびにその使用 |
| JP2023085801A Active JP7790837B2 (ja) | 2015-12-15 | 2023-05-24 | キメラ及びヒト化抗ヒトｃｔｌａ４モノクローナル抗体ならびにその使用 |
| JP2025130097A Pending JP2025160458A (ja) | 2015-12-15 | 2025-08-04 | キメラ及びヒト化抗ヒトｃｔｌａ４モノクローナル抗体ならびにその使用 |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US10618960B2 (enExample) |
| EP (2) | EP4374926A3 (enExample) |
| JP (5) | JP6858779B2 (enExample) |
| KR (2) | KR102830926B1 (enExample) |
| CN (2) | CN108430499B (enExample) |
| AU (3) | AU2016370648B2 (enExample) |
| BR (1) | BR112018012113A2 (enExample) |
| CA (1) | CA3006984C (enExample) |
| DK (1) | DK3389699T5 (enExample) |
| ES (1) | ES2979210T3 (enExample) |
| FI (1) | FI3389699T3 (enExample) |
| HR (1) | HRP20240719T1 (enExample) |
| HU (1) | HUE066907T2 (enExample) |
| IL (3) | IL259988B2 (enExample) |
| LT (1) | LT3389699T (enExample) |
| MX (3) | MX2018006925A (enExample) |
| MY (1) | MY186974A (enExample) |
| PL (1) | PL3389699T3 (enExample) |
| PT (1) | PT3389699T (enExample) |
| RS (1) | RS65703B1 (enExample) |
| SG (1) | SG11201804969PA (enExample) |
| SI (1) | SI3389699T1 (enExample) |
| SM (1) | SMT202400211T1 (enExample) |
| TW (1) | TWI739781B (enExample) |
| WO (1) | WO2017106372A1 (enExample) |
| ZA (1) | ZA201804077B (enExample) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2986765A1 (en) | 2015-05-29 | 2016-12-08 | Agenus Inc. | Anti-ctla-4 antibodies and methods of use thereof |
| EP3515489B1 (en) | 2016-09-19 | 2025-11-05 | OncoC4, Inc. | Cd80 and cd86 binding protein compositions and uses thereof |
| FI3551660T3 (fi) | 2016-12-07 | 2023-12-11 | Agenus Inc | Anti-ctla-4-vasta-aineita ja niiden käyttömenetelmiä |
| CN111511762B (zh) | 2017-08-21 | 2025-05-06 | 天演药业公司 | 抗cd137分子及其用途 |
| AU2018366199A1 (en) * | 2017-11-08 | 2020-05-28 | Xencor, Inc. | Bispecific and monospecific antibodies using novel anti-PD-1 sequences |
| AU2019214865B2 (en) * | 2018-02-02 | 2025-04-10 | OncoC4, Inc. | Mutant anti-CTLA-4 antibodies with improved immunotherapeutic effect but attenuated adverse effects |
| WO2019148444A1 (en) * | 2018-02-02 | 2019-08-08 | Adagene Inc. | Anti-ctla4 antibodies and methods of making and using the same |
| EP3746122A4 (en) * | 2018-02-02 | 2021-11-24 | OncoC4, Inc. | SAFER AND MORE EFFECTIVE ANTI-CTLA-4 ANTIBODY SELECTION AND DESIGN PROCESSES FOR CANCER THERAPY |
| WO2019148445A1 (en) | 2018-02-02 | 2019-08-08 | Adagene Inc. | Precision/context-dependent activatable antibodies, and methods of making and using the same |
| CN112399973B (zh) | 2018-06-05 | 2022-12-16 | 江苏康宁杰瑞生物制药有限公司 | 二聚体及其用途 |
| EP3617230A1 (en) * | 2018-09-03 | 2020-03-04 | BioInvent International AB | Novel antibodies and nucleotide sequences, and uses thereof |
| CN113614109A (zh) | 2018-12-21 | 2021-11-05 | Ose免疫疗法公司 | 双功能抗pd-1/il-7分子 |
| CN114008071B (zh) * | 2018-12-27 | 2025-01-21 | 吉加根公司 | 抗ctla-4结合蛋白及其使用方法 |
| WO2020165374A1 (en) | 2019-02-14 | 2020-08-20 | Ose Immunotherapeutics | Bifunctional molecule comprising il-15ra |
| AU2020406083A1 (en) | 2019-12-17 | 2022-06-16 | Boehringer Ingelheim International Gmbh | Bifunctional molecules comprising an IL-7 variant |
| KR20220166795A (ko) * | 2020-04-13 | 2022-12-19 | 바이오션, 인코포레이티드 | Ctla4에 결합하는 항체 및 이의 용도 |
| AU2021262609A1 (en) | 2020-05-01 | 2022-12-22 | Kashiv Biosciences, Llc | An improved process of purification of protein |
| WO2022112198A1 (en) | 2020-11-24 | 2022-06-02 | Worldwide Innovative Network | Method to select the optimal immune checkpoint therapies |
| EP4255929A2 (en) | 2020-12-02 | 2023-10-11 | Vib Vzw | An ltbr agonist in combination therapy against cancer |
| KR20220112208A (ko) * | 2021-02-03 | 2022-08-10 | 주식회사 유틸렉스 | 항 ctla-4 항체 및 이의 용도 |
| US20240182572A1 (en) | 2021-04-09 | 2024-06-06 | Ose Immunotherapeutics | Scaffold for bifunctional molecules comprising pd-1 or cd28 and sirp binding domains |
| WO2022214653A1 (en) | 2021-04-09 | 2022-10-13 | Ose Immunotherapeutics | New scaffold for bifunctional molecules with improved properties |
| JP7345889B2 (ja) * | 2021-06-17 | 2023-09-19 | 株式会社ニューギン | 遊技機 |
| WO2023057994A1 (en) * | 2021-10-08 | 2023-04-13 | Kashiv Biosciences, Llc | Separation of pre-peak in fusion protein sample by using size exclusion high performance liquid chromatography |
| AU2022361768A1 (en) * | 2021-10-08 | 2024-05-02 | Kashiv Biosciences, Llc | Separation of pre-peak and post-peak in fusion protein sample by using size exclusion high performance liquid chromatography |
| EP4431528A1 (en) * | 2021-10-29 | 2024-09-18 | Longbio Pharma (Suzhou) Co., Ltd. | Isolated antigen binding protein and use thereof |
| CN118176021A (zh) | 2021-10-29 | 2024-06-11 | 昂科医药 | 抗ctla-4抗体给药方案 |
| WO2024003360A1 (en) | 2022-07-01 | 2024-01-04 | Institut Curie | Biomarkers and uses thereof for the treatment of neuroblastoma |
| EP4565610A1 (en) | 2022-08-02 | 2025-06-11 | Ose Immunotherapeutics | Multifunctional molecule directed against cd28 |
| WO2024059833A1 (en) | 2022-09-16 | 2024-03-21 | OncoC4, Inc. | Use of anti-ctla-4 antibodies for treating adenoid cystic carcinoma |
| EP4680728A1 (en) | 2023-03-17 | 2026-01-21 | Quell Therapeutics Limited | Treg therapy |
| JP2026512425A (ja) | 2023-03-30 | 2026-04-16 | オーエスイー・イミュノセラピューティクス | 免疫細胞増強分子の発現のための活性化免疫細胞に標的化された脂質ベースのナノ粒子及びその使用 |
| EP4687990A1 (en) | 2023-03-30 | 2026-02-11 | Ose Immunotherapeutics | Method of synthesis of targeted lipid nanoparticle and uses thereof |
| MX2025012859A (es) | 2023-04-28 | 2026-02-03 | Oncoc4 Inc | Combinaciones de anticuerpos anti-ctla-4 y anticuerpos anti-pd-1 y usos terapeuticos de los mismos |
| EP4724498A2 (en) * | 2023-06-09 | 2026-04-15 | The Regents of the University of California | Methods for identifying and correcting tumor humoral immune dysfunction |
| WO2025133186A1 (en) | 2023-12-22 | 2025-06-26 | OncoC4, Inc. | Anti-ctla-4 antibody for treatment of patients with prostate cancer and combination therapy with a radioligand therapeutic agent |
| WO2025201659A1 (en) | 2024-03-28 | 2025-10-02 | BioNTech SE | Combination therapy comprising therapeutic rna cancer vaccines and anti-ctla4 antibodies for cancer treatment |
| WO2025234450A1 (ja) * | 2024-05-08 | 2025-11-13 | 学校法人帝京平成大学 | 改変がん細胞及びそれを含むがんワクチン組成物 |
| WO2025242835A1 (en) | 2024-05-22 | 2025-11-27 | Ose Immunotherapeutics | Molecules comprising masking linkers and uses thereof for the treatment of cancer |
| WO2026041780A2 (en) | 2024-08-23 | 2026-02-26 | BioNTech SE | Combination therapy comprising anti-ctla4 antibodies and chemotherapy for cancer treatment |
| WO2026057739A1 (en) | 2024-09-12 | 2026-03-19 | BioNTech SE | Combination therapy comprising anti-ctla4 antibodies and anti-pd-1 antibodies for platinum-resistant ovarian cancer treatment |
| WO2026068705A1 (en) | 2024-09-26 | 2026-04-02 | Ose Immunotherapeutics | Lipid-based nanoparticles comprising non-glycosylated fc domains and uses thereof |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| MXPA02001878A (es) | 1999-08-23 | 2003-08-20 | Dana Farber Cancer Inst Inc | Moleculas b7-4 novedosas y usos de las mismas. |
| PT1210428E (pt) | 1999-08-23 | 2015-07-21 | Genetics Inst Llc | Pd-1, um recetor para b7-4 e suas utilizações |
| US7605238B2 (en) * | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| US6803192B1 (en) | 1999-11-30 | 2004-10-12 | Mayo Foundation For Medical Education And Research | B7-H1, a novel immunoregulatory molecule |
| EP1234031B2 (en) | 1999-11-30 | 2021-11-24 | Mayo Foundation For Medical Education And Research | B7-h1, a novel immunoregulatory molecule |
| EP1261376A1 (en) | 2000-01-27 | 2002-12-04 | Genetics Institute, LLC | Antibodies against ctla4(cd152), conjugates comprising same, and uses thereof |
| US7794710B2 (en) | 2001-04-20 | 2010-09-14 | Mayo Foundation For Medical Education And Research | Methods of enhancing T cell responsiveness |
| CA2466279A1 (en) | 2001-11-13 | 2003-05-22 | Dana-Farber Cancer Institute, Inc. | Agents that modulate immune cell activation and methods of use thereof |
| WO2004056875A1 (en) | 2002-12-23 | 2004-07-08 | Wyeth | Antibodies against pd-1 and uses therefor |
| EP1793858A4 (en) * | 2004-09-08 | 2008-12-10 | Univ Ohio State Res Found | HUMAN MONOCLONAL ANTI-CTLA4 ANTIBODIES FOR CANCER TREATMENT |
| WO2006029220A2 (en) * | 2004-09-08 | 2006-03-16 | Ohio State University Research Foundation | Combination therapy with anti-ctla4 and anti-4-1bb antibodies |
| CN101076807B (zh) | 2004-10-15 | 2014-09-03 | 弗里塞恩公司 | 一次性密码验证的方法和系统 |
| CN101146826A (zh) * | 2005-01-24 | 2008-03-19 | 得克萨斯大学体系董事会 | 与磷脂酰丝氨酸结合的fc融合构建体及其治疗用途 |
| PL2161336T5 (pl) * | 2005-05-09 | 2017-10-31 | Ono Pharmaceutical Co | Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi |
| CA2612241C (en) | 2005-07-01 | 2018-11-06 | Medarex, Inc. | Human monoclonal antibodies to programmed death ligand 1 (pd-l1) |
| US8062852B2 (en) | 2007-10-01 | 2011-11-22 | The Children's Hospital And Regional Medical Center | Detection and treatment of autoimmune disorders |
| CN101628940B (zh) * | 2008-07-15 | 2011-11-23 | 中国科学院生物物理研究所 | 一种单克隆抗体及其应用 |
| GB0903325D0 (en) * | 2009-02-26 | 2009-04-08 | Univ Aberdeen | Antibody molecules |
| GB201103955D0 (en) * | 2011-03-09 | 2011-04-20 | Antitope Ltd | Antibodies |
| HRP20200744T1 (hr) * | 2011-12-22 | 2020-07-24 | F. Hoffmann - La Roche Ag | Organizacija ekspresijskog vektora, novi postupci generiranja proizvodnje stanica i njihova uporaba za rekombinantnu proizvodnju polipeptida |
| WO2013142796A2 (en) * | 2012-03-23 | 2013-09-26 | Bristol-Myers Squibb Company | Methods of treatments using ctla4 antibodies |
| EP2925350B1 (en) * | 2012-12-03 | 2019-01-30 | Bristol-Myers Squibb Company | Enhancing anti-cancer activity of immunomodulatory fc fusion proteins |
| US20160145355A1 (en) * | 2013-06-24 | 2016-05-26 | Biomed Valley Discoveries, Inc. | Bispecific antibodies |
| CN104292334B (zh) * | 2014-04-25 | 2018-11-27 | 河南省健康伟业生物医药研究股份有限公司 | 一种全人源抗ctla-4单克隆抗体、制备方法及应用 |
| EP3515489B1 (en) | 2016-09-19 | 2025-11-05 | OncoC4, Inc. | Cd80 and cd86 binding protein compositions and uses thereof |
-
2016
- 2016-12-14 SI SI201631826T patent/SI3389699T1/sl unknown
- 2016-12-14 KR KR1020187017368A patent/KR102830926B1/ko active Active
- 2016-12-14 IL IL259988A patent/IL259988B2/en unknown
- 2016-12-14 IL IL310404A patent/IL310404A/en unknown
- 2016-12-14 EP EP24164173.7A patent/EP4374926A3/en active Pending
- 2016-12-14 BR BR112018012113-4A patent/BR112018012113A2/en active Search and Examination
- 2016-12-14 IL IL296354A patent/IL296354B2/en unknown
- 2016-12-14 SM SM20240211T patent/SMT202400211T1/it unknown
- 2016-12-14 EP EP16876612.9A patent/EP3389699B1/en active Active
- 2016-12-14 AU AU2016370648A patent/AU2016370648B2/en active Active
- 2016-12-14 DK DK16876612.9T patent/DK3389699T5/da active
- 2016-12-14 HR HRP20240719TT patent/HRP20240719T1/hr unknown
- 2016-12-14 SG SG11201804969PA patent/SG11201804969PA/en unknown
- 2016-12-14 WO PCT/US2016/066698 patent/WO2017106372A1/en not_active Ceased
- 2016-12-14 CN CN201680073425.2A patent/CN108430499B/zh active Active
- 2016-12-14 HU HUE16876612A patent/HUE066907T2/hu unknown
- 2016-12-14 JP JP2018530560A patent/JP6858779B2/ja active Active
- 2016-12-14 US US16/062,350 patent/US10618960B2/en active Active
- 2016-12-14 PT PT168766129T patent/PT3389699T/pt unknown
- 2016-12-14 CN CN202210802423.XA patent/CN116063492A/zh active Pending
- 2016-12-14 KR KR1020257022200A patent/KR20250108763A/ko active Pending
- 2016-12-14 RS RS20240735A patent/RS65703B1/sr unknown
- 2016-12-14 MY MYPI2018000904A patent/MY186974A/en unknown
- 2016-12-14 FI FIEP16876612.9T patent/FI3389699T3/fi active
- 2016-12-14 ES ES16876612T patent/ES2979210T3/es active Active
- 2016-12-14 LT LTEPPCT/US2016/066698T patent/LT3389699T/lt unknown
- 2016-12-14 MX MX2018006925A patent/MX2018006925A/es unknown
- 2016-12-14 CA CA3006984A patent/CA3006984C/en active Active
- 2016-12-14 PL PL16876612.9T patent/PL3389699T3/pl unknown
- 2016-12-15 TW TW105141656A patent/TWI739781B/zh active
-
2018
- 2018-06-07 MX MX2025001302A patent/MX2025001302A/es unknown
- 2018-06-07 MX MX2025001300A patent/MX2025001300A/es unknown
- 2018-06-18 ZA ZA2018/04077A patent/ZA201804077B/en unknown
-
2020
- 2020-02-27 US US16/803,972 patent/US11629188B2/en active Active
-
2021
- 2021-03-23 JP JP2021049294A patent/JP2021100957A/ja active Pending
-
2022
- 2022-06-15 JP JP2022096901A patent/JP7286845B2/ja active Active
-
2023
- 2023-03-22 US US18/188,098 patent/US12473362B2/en active Active
- 2023-05-19 AU AU2023203169A patent/AU2023203169B2/en active Active
- 2023-05-24 JP JP2023085801A patent/JP7790837B2/ja active Active
-
2025
- 2025-08-04 JP JP2025130097A patent/JP2025160458A/ja active Pending
-
2026
- 2026-02-05 AU AU2026200849A patent/AU2026200849A1/en active Pending